Global consultation on cancer staging: promoting consistent understanding and use by Brierley, James et al.
Determination and documentation of the extent of 
disease in a patient is a prerequisite activity in starting 
the process of cancer care. For more than 70 years the 
anatomical extent of disease, or cancer stage, has been 
classified using the tumour- node-metastasis (TNM) 
classification, although, with evolving knowledge, many 
other factors have been recognized to also influence 
prognosis1,2. Some factors relate to patient characteris-
tics (such as age and performance status), while others 
reflect more detailed tumour- specific elements that 
might reflect disease trajectory (such as hormone recep-
tor status in women with breast cancer) or that might 
enable a more precise diagnosis (such as the presence 
of human papillomavirus DNA in patients with oro-
pharyngeal cancer). Indeed, Pierre Denoix, who devel-
oped the original TNM classification, acknowledged 
that many factors other than the anatomical extent of 
disease can contribute to prognosis3. Unfortunately, 
attempts to include these additional factors in staging 
classification systems to date have led to increasing levels 
of miscommunication regarding the goals of cancer clas-
sification and variability in the application of such classi-
fications in clinical research and practice and in cancer 
surveillance. Notably, cancer staging is not only used to 
define prognosis but is also applied to guide patient care; 
consistent staging is also vital in enabling cancer sur-
veillance, in epidemiological studies and in the broader 
field of cancer control. Eventually, if an increasing vari-
ety of prognostic factors are included in future staging 
systems without careful adherence to logical and con-
sistent principles, these classifications would no longer 
provide a distinct construct that accurately reflects the 
anatomical extent of disease. The exact description of 
disease burden might shift with refinements in meth-
ods of assessment, such as imaging, resulting in stage 
migration4. The availability and measurement of ana-
tomical disease stage is more likely to be consistent over 
time and across different geographical areas compared 
with the ever changing field of molecular prognostic 
factors5,6. These other factors, biomarkers and measures 
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of biological activity are more vulnerable to the many 
vagaries that can accumulate over time, including those 
emerging from new discoveries, assay development and 
clinical validation5,7. Furthermore, a potential biomarker 
might not be clinically relevant across the entire disease 
spectrum but might be highly effective in a specific 
anatomically defined subset of patients. For example, 
gene expression profiling provides valuable informa-
tion on prognosis among patients with lymph node- 
positive (stage III) melanoma, but not in those with 
earlier stage disease8,9.
To clarify the objectives of cancer staging and pro-
mote its correct and consistent use, a Global Consultation 
on Cancer Staging was convened under the auspices of 
the Union for International Cancer Control (UICC), the 
US National Cancer Institute (NCI), and the Centers 
for Disease Control and Prevention (CDC) (Box 1). The 
aim of the Consultation was to review, discuss and pro-
mote the consistent understanding and use of cancer 
staging terminology.
Development of cancer staging
The TNM system for the classification of disease extent 
was originally designed with the intention of quantifying 
the anatomical burden of cancer. Owing to the consist-
ent, robust associations between anatomical extent of 
disease and patient outcomes, the TNM classification 
became synonymous with prognosis. The overarching 
importance of obvious, clinically apparent anatom-
ical extent of disease to prognostication and clinical 
decision- making and the simplicity and ease of use of 
the TNM system led to the adoption of this classification 
system worldwide1,10,11. Over the ensuing years, several 
additional prognostic factors have occasionally been 
incorporated into staging classifications. Examples of 
these factors include patient age in the classification 
of differentiated thyroid cancers and histological grade 
in those designed for soft tissue and bone sarcomas, as 
well as the development of prognostic classifications 
for certain cancers, such as gestational trophoblastic 
neoplasms and lymphomas11,12.
The UICC, which has provided stewardship and ena-
bled the development of the TNM classification from its 
origin onwards, also has a mandate to address the wide- 
ranging issues surrounding population- based cancer 
control, including the need to maintain a staging classi-
fication system that is relevant to an extensive group of 
stakeholders, such as the CDC, the International Agency 
for Research in Cancer (IARC), the  International 
Association of Cancer Registries (IACR), and the 
International Cancer Benchmarking Partnership 
(ICBP). Appreciating that cancer registries are depend-
ent upon consistent cancer staging and that many reg-
istries throughout the world have limited resources, 
the UICC collaborated with the IARC to develop the 
Essential TNM Classification, which is designed for 
use in resource- limited settings12,13. The UICC has also 
expended considerable effort in documenting and classi-
fying the various nonanatomical prognostic factors that 
must be considered in clinical care2.
Since 1959, the American Joint Commission on 
Cancer (AJCC) has published its own TNM classifica-
tion14. The AJCC was initially formed to evaluate the 
recommendations of the UICC TNM committee and to 
make suggestions or offer alternate classifications based 
on the TNM that were considered to be more suitable for 
use by physicians based in North America15. However, 
starting with the fourth edition in 1987, the aim is to 
ensure as little difference as possible between the two 
classifications7,9, and the UICC and AJCC strive to use 
congruent definitions, although the wording used in 
each version is not always exactly the same owing to 
differences in the traditional formalizations and styles 
used by the two organizations. With each new edition, 
some differences also arise, typically owing to topo-
graphical or formatting errors that have been corrected 
in respective websites and new printings. The AJCC has 
also made considerable efforts to improve the classifica-
tion with the goal of enabling more accurate prediction 
of survival by including additional factors in its pro-
gnostic groups, which are also mirrored in the UICC 
prognostic groups discussed below.
In addition to the UICC and AJCC TNM classi-
fications, other cancer staging systems exist and are 
used both for clinical and research purposes, includ-
ing the International Federation of Gynecology and 
Obstetrics (FIGO) staging system, which is used for 
clinical, research and surveillance purposes, and the 
Surveillance, Epidemiology and End Results (SEER) 
Extent of Disease (EOD) classification, which is mainly 
used by the cancer surveillance community16. Members 
of the UICC TNM project also collaborate with the net-
work of national and regional TNM committees, with 
the AJCC and FIGO, as well as the CDC, the World 
Health Organization (WHO) and the IARC to maintain 
a high level of uniformity between classification systems 
wherever possible11,12,17.
Axes of cancer classification. Cancers are a heterogene-
ous group of diseases and are generally classified using 
the WHO International Classification of Diseases for 
Oncology (ICD- O), which includes topography and 
morphology codes18. The diseases are further charac-
terized along two main lines — histological and molec-
ular characteristics, and anatomical extent. Pathological 
classification criteria are outlined in the universally 
adopted WHO Classification of Tumours series (the 
so- called Blue Books), which provide an authoritative 
and concise resource for the histological and molecular 
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Box 1 | Participants in the global Consensus Meeting
AJCC, American Joint Commission on Cancer; CDC, Centers 
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Cancer; ICCR, International Collaboration on Cancer 
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classification of tumours. While recognizing these 
important paradigms, the anatomical extent of disease 
remains important and, in many instances, continues to 
be the most important determinant of patient outcome 
and is captured in the TNM staging classification.
Treatment and prognosis. Cancer stage classification 
serves many purposes (Box 2), including patient care, 
prognostication and obtaining data to guide cancer 
control and research. A large constellation of factors 
influence prognosis, and these factors can relate to the 
tumour, the patient, and factors external to the patient 
or the patient’s environment, such as social determi-
nants of health, including access and quality of health-
care (or treatment setting). These are important in the 
context of cancer management and, indeed, can affect 
all aspects of cancer control including clinical prac-
tice, research and surveillance, and the development, 
provision and maintenance of cancer systems and pro-
grammes. Some of these factors are remediable, such 
as access to quality care, while many are more diffi-
cult to ameliorate and often form part of the intrinsic 
characteristics of the tumour (such as tumour pathol-
ogy). No uniformly accepted framework for classifying 
and/or integrating these factors into tumour stag-
ing currently exists, although attempts to incorporate 
one or more of these factors into staging classification 
frequently emerge19–21.
The UICC has maintained a traditional formaliza-
tion that emphasizes staging based on anatomy, wherein 
the T, N, and M categories are combined into groups 
termed ‘stage’, with essential prognostic factors presented 
separately. In this way, the contribution of both the ana-
tomical and nonanatomical domains can be differen-
tially appreciated, thereby facilitating future revisions. 
In selected tumour histologies (such as thyroid cancers 
and sarcomas, as noted above) the UICC traditionally 
combined information on T, N, and M with other non-
anatomical prognostic factors to maintain agreement 
with the AJCC (it was considered inappropriate to sub-
sequently reverse this decision for these few cancers). 
The AJCC adopts a different approach, with a single 
grouping system applied following definition of the cat-
egories, referring to these as ‘prognostic stage groups’. 
When anatomical factors only are considered for the 
AJCC ‘prognostic stage groups’, these are identical to 
the UICC ‘stage’. In turn, the UICC ‘prognostic groups’ 
are identical to the AJCC ‘prognostic stage groups’ in 
the rarer situations in which nonanatomical factors are 
included in the UICC definition. In breast cancer, the 
AJCC provides cancer- specific prognostic stage groups 
that combine measures of the anatomical extent of dis-
ease with those of essential nonanatomical prognostic 
factors, while also retaining anatomical stage groups that 
consist of the anatomical extent of disease which is solely 
recommended for use in geographical regions in which 
the necessary biomarker tests are unavailable11,12.
Stakeholders. Multiple stakeholders rely on accurate 
cancer staging, potentially the most important being 
the patients themselves, in partnership with their phy-
sicians who require an indication of prognosis to make 
informed treatment decisions. Researchers, especially 
those involved in clinical trials, use information on 
staging to both select and stratify patients and to plan 
relevant clinical studies. Cancer registries and epidemi-
ologists rely on accessible synoptic depictions of disease 
extent (including disease stage) across populations to 
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understand patterns of presentation and differences in 
patient outcome, plan research projects, and study the 
effects of population- based screening and early detec-
tion programmes on disease stage at presentation22–27. 
Agencies with a role in cancer control also have an inter-
est in disease stage at presentation, as this information 
can be used to guide resource allocation and to monitor 
compliance with treatment guidelines12,25,28–30.
The comparison of outcomes between jurisdictions 
and in a given population relies on the staging classi-
fications and definitions being applied uniformly both 
across and within specific populations, and on consistent 
use of language and/or terminology. Indeed, inconsist-
encies in the classifications have hampered the com-
parisons of outcomes across geographical regions and 
nations as described by the ICBP and addressed in more 
detail below31. Thus, it is important for the classification 
to be consistent and to follow the published guidelines.
The requirement for staging systems that serve the 
needs of multiple stakeholders creates various chal-
lenges. Some stakeholders require classifications to be 
as simple and as stable over time as possible, while oth-
ers prefer a more detailed classification that enables the 
rapid incorporation of new knowledge that is relevant 
to current clinical practice5. Thus, obtaining consen-
sus through dialogue and agreement between different 
stakeholders remains a continued necessity.
Consequences of inconsistent application
Inconsistent cancer staging can arise from misuse of 
the nomenclature. The potential for confusion exists in 
many areas, including the use of the T, N and M cate-
gories, the stage groups, the definitions of what consti-
tutes clinical versus pathological extent of disease; and 
the definition of extent of disease at diagnosis versus 
following treatment. Adding to the confusion, commu-
nication regarding cancer stage between two or more 
populations can be hampered by inconsistent use of dif-
ferent staging classifications, use of different editions of 
the TNM classification and/or a lack of reporting of the 
specific classification and edition being used. The ICBP 
investigated disease stage at diagnosis and stage- specific 
survival using population- based cancer registry data 
obtained from six economically developed countries31. 
The study was hindered by a lack of information on dis-
ease stage (for example, availability was often limited to 
grouped TNM data, without reporting of the individual 
component T, N and M variables) and by substantial lev-
els of variation in the type of stage classifications being 
used (including different editions of the TNM and/or 
the Dukes’ and FIGO systems). The investigators called 
for a global consensus to promote adherence to a single 
staging system31.
Amalgamation of other prognostic factors. Considerable 
interest exists in the use of composite or mixed classi-
fications that embody both disease extent and biology, 
owing to the importance of the additional prognostic 
factors. Such classifications can manifest as modifica-
tions to the T, N or M categories, or within the stage 
groups32–34. A tendency also exists to subdivide disease 
into ‘risk’ subgroups assembled using amalgams of dif-
ferent prognostic factors (for example, high- risk versus 
low- risk disease without identifying a specific outcome 
of interest or the components of the subgroups). Hybrid 
classifications of this type32–34 are typically fraught with 
the potential for confusion regarding understanding 
of the importance and relevance of different individual 
prognostic elements. In turn, this potential for confu-
sion perturbs the purpose of staging as a classification 
reflecting the anatomical extent of disease.
We emphasize that the creation of risk groups or 
strata that are relevant to clinical practice is entirely 
feasible and appropriate once the fundamental compo-
nents (including TNM categories, biological variables 
and others) are established. Composite risk or prognos-
tic groups of this type are often helpful, although they 
also have limitations35–37. Such risk groups are usually 
not generalizable across the full spectrum of disease and 
tend to be specific to anatomy and time- dependent sce-
narios21,38–40. Furthermore, similar to any other classifi-
cations, the boundaries between the individual elements 
might be imprecise. For example, the levels of serum 
tumour biomarkers such as prostate- specific antigen and 
carcinoembryonic antigen are generally correlated with, 
but do not directly correspond to, the anatomical extent 
of disease. As a further example from prostate cancer, a 
high serum prostate- specific antigen level might reflect 
the extent of disease and predict a higher risk of dis-
tant metastasis, although a low level in the presence of 
known disease might be a consequence of poor differ-
entiation41. Some previously accepted parameters, while 
posing challenges to the strict application of the rules 
of the TNM classification, might be accepted as histor-
ical exceptions, such as testicular teratoma. However, 
the existence of a few notable exceptions should not 
lead to the widespread incorporation of a wide range 
of nonanatomical variables into the TNM classification. 
Incorporating such variables increases the risk of not 
recognizing the unique contributions of both tumour 
biology and anatomical disease extent.
The dynamic nature of prognosis. An awareness of 
the outcome being assessed, the specific intervention 
(whether that be observation or treatment), and the 
specific end point under consideration (whether that 
be 5-year survival, local tumour control, organ pres-
ervation, symptom control, or another end point) is 
important when determining a patient’s prognosis. 
The management and prognosis of a patient at the 
time of first presentation of disease is not usually the 
same as when a recurrence becomes apparent later; 
Box 2 | Objectives of cancer staging12
• To aid the clinician in the planning of treatment
• To give some indication of prognosis
• To assist in evaluation of the results of treatment
• To facilitate the exchange of information between 
treatment centres
• To contribute to the continuing investigation of human 
cancer
• To support cancer control activities
www.nature.com/nrclinonc
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the consequences of recurrent disease might also differ 
appreciably depending on the location of the recur-
rence (locoregional compared with distant disease). 
These steps in the illness need to be considered sepa-
rately because prognosis, prognostic factors, treatment 
options and outcomes are all likely to differ. In this way, 
the steps along the disease trajectory of a patient with 
cancer can be considered a series of scenarios. Even 
within certain scenarios, nuances might exist depending 
on how the first treatment evolves, and whether com-
plications or additional problems emerge (such as the 
need for adjuvant treatment owing to adverse findings 
uncovered during initial surgery). Numerous scenarios 
in which both prognosis and prognostic factors can vary 
might exist for any patient during the course of their 
illness. In this way, prognosis can only be accurately 
defined in scenario- specific contexts (such as at initial 
presentation, at recurrence, or following the emergence 
of distant metastases) that include the effects of other 
prognostic factors and of the interventions administered 
at that time42,43.
The consultation (planning and structure)
The UICC TNM Project, under the auspices of the NCI 
and the CDC, held the Global Consultation on Cancer 
Staging (GCCS) in 2017 to address the aforementioned 
issues of consistency and universal utility. The aim of 
this consultation was to reach agreement on the optimal 
use of cancer staging classification terminology and on 
stage definitions44 (Box 3). The discussions were limited 
to the role of the anatomical extent of cancer (cancer 
stage) and the terminology related to the stage, staging 
classification and the process of cancer staging. Other 
prognostic considerations relating to cancer biology, 
patient or host characteristics, and the environment that 
might influence quality of or access to care were deferred 
to a subsequent consultation designed to address this 
broader scope of prognosis and patient outcome.
An initial preparatory phase of the GCCS was under-
taken to confirm the diverse use of staging terminology. 
A panel of international experts on the use of cancer 
staging was convened to investigate and evaluate the 
impressions of the UICC TNM Core Committee. 
The members of the UICC TNM Project, in consultation 
with the US NCI SEER Project and the AJCC, convened 
a planning group that also included representatives 
from the IARC, IACR, the International Collaboration 
on Cancer Reporting (ICCR) and the NCI. This group 
identified issues to be addressed and the appropriate 
interested stakeholders to survey. A survey of cancer 
clinicians and cancer registry community professionals 
was conducted to assess the current use of cancer stage 
terminology. Examples from the literature further con-
firmed the prevalent heterogeneous use of the concept 
of cancer staging and the related terminology.
A second phase included a face- to-face meeting of 
major stakeholders and users of cancer staging systems, 
in which current challenges to the consistent application 
of staging classification were presented and discussed in 
detail. The consultation focused on achieving agreement 
on how staging rules should be interpreted and applied.
Survey on the use of terminology. An online survey was 
initially piloted among 10 independent experts. The 
survey was then refined for clarification of language 
and content and distributed to 463 TNM users world-
wide who were randomly selected from a database of 
email addresses provided by several major TNM user 
groups: the UICC TNM Core Group; the UICC Expert 
Panels and Global Advisory Groups; the UICC Manual 
of Clinical Oncology authors; SEER Directors and 
Managers; The Canadian Council of Cancer Registries; 
and the IACR and AJCC Editorial Board and Expert 
Panels. In total, 143 (31% of selected TNM users) 
responded. The survey comprised 35 questions focusing 
on four different domains: application of the TNM clas-
sification; cancer stage terminology; prognostic factors; 
and prognostic classifications.
Analysis of the survey data revealed that 87.5% of 
respondents believed that the application of the TNM 
staging terminology is inconsistent in the literature. 
A large majority (85% of respondents) confirmed that 
multiple stakeholders use data on tumour stage; these 
include clinicians and patients when estimating prog-
nosis and selecting treatments, researchers to facilitate 
clinical trial eligibility and stratification as well as when 
undertaking translational studies, and cancer control 
professionals when exploring cancer behaviour. A large 
majority (85% of respondents) also believed that individ-
ual T, N, and M categories, in addition to information on 
roman numeral stage grouping, should be recorded in 
both national and regional cancer registries. In addition 
to the TNM, 71% of respondents reported that infor-
mation on other prognostic factors should also be col-
lected by cancer registries, although 85% stipulated that 
information on the anatomical extent of disease should 
be collected as a separate and distinct variable. Many 
respondents (81%) reported that tumour biomarkers 
and other prognostic factors are important independ-
ent determinants of prognosis, but also that no over-
arching framework for classifying such factors can be 
applied for all cancers. No consensus emerged on how 
Box 3 | Process and methods: the global Consultation on Cancer Staging
Planning phase: a panel of international experts on cancer staging was convened
• To confirm the need for a consultation
• To plan the consultation
Literature review:
• To identify inconsistencies in the use of cancer staging classification terminologies
• Target literature reviewed included English language items published in 12 high- impact 
journals between July 2016 and December 2016.
A stakeholder survey was undertaken to evaluate the current understanding and use  
of terminology surrounding cancer stage classification
• 35 questions were prepared following a pilot study
• Addressed application of TNM, cancer stage terminology, prognostic factors and 
prognostic classifications
The Global Consultation on Cancer Staging
• To engage experts on cancer staging, global health, cancer care and clinical research
• To discuss inconsistencies in the use of cancer staging terminologies
• To develop consensus on cancer staging terminologies
TNM, tumour- node-metastasis.
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the TNM and other prognostic factors could be com-
bined. Regarding cancer staging terminology, the major-
ity of the respondents confirmed the view that the effects 
of stage migration are similar to the Will Rogers phe-
nomenon, whereby changes in staging criteria can lead 
to spurious improvements in prognosis at certain dis-
ease stages, but most believed that stage shift is the same 
as stage migration4. The majority of respondents (61%) 
defined tumour downstaging rather than downsizing as 
a reduction in the size of a tumour after neoadjuvant 
therapy. In addition, no clear definition of the term 
‘understaging’ emerged. The answers to the final sec-
tion of the survey on terminology formed the basis of a 
list of definitions that were revised and confirmed at the 
Global Consultation Conference (BoxES 4–6).
Inconsistent use of staging terminology. To better appre-
ciate the level of inconsistency in the use and mean-
ing of terms employed in cancer staging classification, 
pathological classification, biomarkers, tumour pro-
file and prognostic group definitions, we conducted 
a limited review of the literature involving all articles 
published in any of 12 selected high- impact oncology 
journals between July and December 2016. The jour-
nals were screened for published articles (clinical trials, 
prospective and retrospective studies and review arti-
cles) pertaining to cancer staging, prognostic factors, 
prognostic groups and tumour pathology and/or pro-
file classification. Inconsistent understanding and use 
of stage terminology was found in 20% of the reviewed 
literature (Box 7). Incorrect definitions of cancer stage 
and TNM categories were the most prevalent incon-
sistencies, with a variety of nonstandard terms such 
as ‘T stage’, ‘T group’, ‘T status’ and others being used 
instead of the officially designated terms ‘T category’ 
or ‘TNM stage’. Furthermore, somewhat random use 
of the terms discussed in the survey results was also 
identified; ‘downsizing’, ‘upsizing’ and ‘understaging’ 
were all evident and applied in different scenarios with-
out clear explanations or definitions. ‘Downstaging’ and 
‘downstage’ were used both as a noun and verb and were 
defined inconsistently. Similarly, the terms ‘stage shift’ 
and ‘stage migration’ were defined in multiple ways and 
applied inconsistently. The published literature also 
included information on post- treatment factors (such 
as the status of tumour resection margins), together 
with baseline pretreatment factors, when reporting the 
clinical TNM stage. Information on tumour biomark-
ers was frequently combined with information on the 
anatomical extent of disease. Furthermore, in some 
articles38, temporally distinct patient populations were 
combined into a single population, such as the inclu-
sion of information on the characteristics of patients 
with primary and those with recurrent tumours within 
the same group.
The Consultation Meeting. The GCCS meeting was held 
in London, UK. Experts from the UICC, AJCC, NCI, 
CDC, FIGO, IACR, IARC and the ICCR participated. 
A general agreement was reached regarding the observed 
challenges and the needs of the consultation as detailed 
above, and the details of the literature review and the 
survey results were analysed to fully appreciate the extent 
of variability in the application of the T, N, M and can-
cer staging terminology. The participants reaffirmed the 
purpose of the staging classification, discussed the pro-
cess of staging and the importance of applying it within 
the appropriate clinical scenario, recognized the scope 
of TNM staging, provided guidance for its appropriate 
use, and discussed and agreed upon the definitions of 
relevant terms (BoxES 4–6). A unanimous consensus 
was reached that anatomical extent of disease and other 
prognostic factors should be considered and presented 
separately. Lessons learned through the GCCS will be 
adopted and implemented in the next iteration of the 
TNM classification, the TNM ninth Edition.
Next steps
The most important definitions and usage conventions 
relating to the TNM classification should be dissem-
inated further to ensure consistent application and 
use among practitioners, researchers and cancer reg-
istry personnel. Both the introduction section of the 
UICC TNM Classification and Chapter 1 of the AJCC 
Cancer Staging Manual describe the rules and conven-
tions of cancer staging using the TNM classification. 
Existing educational tools such as the UICC Helpdesk 
and the introductory site- specific modules and short 
educational videos are available on the UICC website, 
and educational webinars and clinical staging cases 
(staging moments) relating to chapter 1 of the AJCC 
manual are available on the AJCC website and require 
better promotion.
The diverse needs of various stakeholders should be 
better addressed. Cancer registry data should include a 
record of disease stage at initial presentation. A cancer 
registry would not normally classify a different disease 
extent as a criterion for disease progression during 
a period of ‘watchful waiting’ or ‘active surveillance’ 
Box 4 | Fundamental definitions
Cancer stage
• should be defined and recorded at initial diagnosis, and must remain unchanged in 
the medical records.
• While anatomical disease extent may change during patient management, the 
original stage designation should not be amended.
T category, n category, M category
The anatomical extent of disease is based on the assessment of three components:  
the T category, the N category and the M category and should not be termed T stage, 
N  stage, and M stage because the term ‘stage’ is ordinarily reserved for the roman 
numeral aggregated stage groups.
‘Clinical’ and ‘Pathological’ classification
• ‘Clinical classification’ (cTnM): the pretreatment clinical classification is based on 
evidence acquired before any treatment intervention. Such evidence is gathered from 
physical examination, imaging, endoscopy, surgical exploration and other sources.
• ‘Pathological classification’ (pTnM): based on evidence acquired before treatment 
but supplemented or modified by additional information acquired from observations 
during surgery and from pathological examination of surgical specimen(s). This 
therefore requires knowledge of both the clinical and pathological extent of disease 
and cannot be solely determined by the pathologist without full clinical information 
or input.
TNM, tumour- node-metastasis.
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(which is a frequently used approach in the manage-
ment of patients with prostate cancer); by contrast, 
a clinician would be interested in the anatomical extent 
of disease at the time of definitive treatment and would 
usually document the degree of disease progression as 
the patient migrated into a new clinical scenario in this 
manner. The TNM classification rules state that the new 
disease extent should be classified using the ‘r’ prefix to 
reflect recurrent disease if progression occurred (Box 6). 
However, this is not the current practice and merits the 
introduction of an agreed convention. The application 
of the concept of ‘cancer scenario’, as discussed previ-
ously, is therefore encouraged in order to improve the 
consistency of reporting.
Consistency and completeness of reporting would 
be enhanced by applying checklists to facilitate the ver-
ification of the proper use of terminology by journal 
editors and reviewers, for which compliance would be 
required. This action would be similar to the 2005 guide-
lines to improve the quality of reporting of study results, 
such as the Reporting Recommendations for Tumour 
Marker Prognostic Studies (REMARK)45 and those for 
prediction models involving Transparent Reporting 
for Individual Prognosis or Diagnosis (TRIPOD)46.
In the future, methodologies that enable the identi-
fication and inclusion of necessary data elements rel-
evant for personalized treatment need to be explored. 
The UICC has developed prognostic factor tabulations 
that stratify these factors according to their relevance to 
patient management as determined by their inclusion 
in published cancer treatment guidelines. This process 
should be further optimized by collaboration with the 
established national and international evidence- based 
guideline development groups, such as the UK National 
Institute for Health and Care Excellence (NICE), the 
National Comprehensive Cancer Network (NCCN), 
European Society for Medical Oncology (ESMO), 
the International Consortium for Health Outcomes 
Measurement (ICHOM) and others, in order to ensure 
optimal alignment, consistency and value in cancer 
management strategies. The selection of relevant fac-
tors should pay particular attention to their inclusion in 
cancer registries where appropriate.
A consensus emerged from the GCCS meeting that 
the anatomical extent of disease and other prognostic 
factors should be considered separately, but could still 
be combined in the framework as separate ‘prognostic 
groups’ where applicable. The UICC TNM group pub-
lish breast cancer- specific stage and stage groups based 
on anatomical extent of disease and also separately pub-
lish essential prognostic factors required for treatment 
decision- making12. By contrast, the AJCC publishes 
a prognostic classification of breast cancer based on 
anatomical extent of disease combined with essential 
nonanatomical prognostic factors (oestrogen receptor, 
progesterone receptor and human epidermal growth 
factor receptor 2 status, and tumour grade)11. However, 
the AJCC also supports the aforementioned use of stage 
groups in the classification of breast cancers based 
solely on anatomical factors in geographical regions 
where quantification of the necessary biomarkers is 
not possible11.
More formal collaborations with international 
organizations involved in overseeing standards in can-
cer research and treatment should be encouraged and 
Box 6 | Scenario- specific contexts
Restaging is the process of investigating the anatomical 
extent of disease after initial treatment or management. 
All ‘scenarios’ other than initial diagnosis involve 
restaging and require different terminology in order  
to achieve clarity. A prefix should be used as follows:
• After neoadjuvant therapy — ‘y stage’
• after a documented disease- free period (complete 
response) and later recurrence, mandating ‘restaging’ 
— ‘r stage’.
• Anatomical extent of disease after a period of 
surveillance (as observed in prostate or thyroid cancer) 
— ‘r stage’
Downstaging describes a reduction in T (tumour) or  
N (node) category after neoadjuvant therapy
Downsizing describes a reduction in tumour volume 
after neoadjuvant therapy
The terms ‘upstaging’ and ‘understaging’ are 
occasionally used in the literature, and typically relate  
to differences in diagnostic accuracy of various staging 
investigations. We do not recommend the use of these 
terms owing to a lack of precision in understanding  
their meaning.
Box 5 | Stage concepts
Stage migration describes a change in the proportion of T, N or M categories among 
patients within a defined population, following the introduction of a new means 
of assessing the extent of disease.
Stage shift describes a change in the pattern of stage distribution among patients 
within a defined population to a lower disease stage following the introduction of 
early detection or screening programmes, or to a higher disease stage when access 
to care becomes limited.
Clinical TNM categories (and, when available, pathological categories) should 
be recorded at diagnosis in cancer registries and used to determine clinical and 
pathological stage groups. Occasionally, when incomplete information is available in a 
cancer registry, the pathological and clinical data have been combined in order to avoid 
losing information; the consequence otherwise is an inability to assign a stage group. 
In such instances, the resultant stage group is neither a clinical nor pathological stage 
group but a combined version; the term harmonized stage (hTNM) has been proposed 
for such situations to facilitate cancer surveillance. In cancer care, all the variables 
pertaining to the extent of disease should be available to the clinician and the term 
‘harmonized stage’ should not be used.
Stage is applied by the UICC to describe the anatomical extent of disease.
Prognostic group is applied by the uiCC to describe classifications that incorporate 
prognostic factors in addition to the anatomical extent of disease.
Anatomical stage group is applied by the AJCC to classify breast cancers in geographical 
regions in which the required biomarker tests are not readily available to describe the 
anatomical extent of disease.
Prognostic stage group is generally used by the AJCC to describe groups that include 
anatomical extent of disease when combined with other prognostic factors, although 
in many situations the term is limited to the inclusion of anatomical disease extent if 
additional prognostic factors are not included.
Surveillance, Epidemiology, and End Results Extent of Disease (SEER–EOD) is a data 
coding system used by the surveillance community, but not generally by clinicians, 
that applies the terms limited, regional and distant to describe the anatomical extent 
of disease. This system is not straightforward to translate into the TNM system owing to 
substantial differences in the definitions of regional involvement.
AJCC, American Joint Commission on Cancer; TNM, tumour- node-metastasis; UICC, Union for 
International Cancer Control.
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emphasized, and should particularly involve the IARC 
and WHO, in order to reduce inconsistencies in termi-
nology and classifications between those described in 
the WHO Blue Books and the UICC12/AJCC11 classifi-
cations. In this regard, formal collaborations between the 
UICC, AJCC and WHO already exist. In addition to 
the selection and inclusion of relevant nonanatomi-
cal factors in addressing prognosis, the focus needs to 
include appropriate scientific methodologies for analysis 
of more complex emerging data, which are often volumi-
nous and difficult to manage. Such approaches require 
rigour in developing predictive models and consultation 
with and contributions from experts in such analyses.
Conclusions
The management of patients with cancer requires con-
sistent terminology to define and accurately describe 
diagnosis, guide patient management and consider prog-
nosis. Accordingly, cancer surveillance requires consist-
ent definitions and indications to describe disease stage 
at diagnosis at the population level. Diagnosis is generally 
described using universally accepted ICD and ICD- O 
categories and the WHO Classification of Tumours. The 
TNM Classification of Malignant Tumours12 remains 
the standard for recording and classifying anatomical dis-
ease extent. The TNM Classification is neither designed 
nor equipped to encompass the entire spectrum of prog-
nostic and predictive variables in all forms of cancer and 
further progress in developing distinct prognostic clas-
sifications or tools for improved estimation of prognosis 
will be needed in the future. The TNM Classification 
is important for many stakeholders with an interest in 
cancer control; therefore, adherence to precise defini-
tions and using the terminology as designed to optimize 
the accuracy of clinical and scientific communications 
should be a priority. The GCCS has achieved a consensus 
on purpose and definition, in a variety of applications 
of cancer staging. This consultation also reaffirmed the 
need to promote education on the use of cancer staging, 
investigate the issue of cancer prognosis and develop 
methods to more accurately describe and calculate the 
probability of relevant outcomes in patients with cancer.
Published online xx xx xxxx
Box 7 | inconsistancies and incorrect use of terminology
• Incorrect use of T, N and M categories and TNM grouped stage, T or N status, group, 
subgroup and/or substage
• Misunderstanding of downstaging, downsizing and the definitions of other specific 
terms
• Misunderstanding the definition of stage shift
• Misunderstanding the definition of stage migration
• Attempting to define and assess prognosis in mixed patient populations, including 
combining those with primary and recurrent, recurrent and metastatic, or resectable 
and unresectable disease
• Mixing measures of nonbaseline factors and baseline factors in prognostic models
• Mixing tumour profile characteristics and cancer stage classifications to define 
prognosis
TNM, tumour- node-metastasis
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